This specialized case study explores Kymanox’s approach to developing a strategic drug development and regulatory plan for an innovative bio-nano-medicine. Our team of SMEs collaborated closely with stakeholders to implement measurable improvements across formulation assessment, FDA submission, and clinical trial design to ensure development progress and regulatory alignment toward successful market entry.
CHALLENGE
SOLUTION
RESULTS
- Develop a comprehensive drug development strategy for an innovative bio-nano-medicine intended for intravenous injection.
- Provide strategic guidance across Chemistry, Manufacturing, and Controls (CMC), regulatory, nonclinical, and clinical development to meet industry and regulatory expectations.
- Assessed formulation, stability, analytical methods, and Contract Development Manufacturing Organization (CDMO) selection to close critical technical information gaps.
- Drafted a detailed Request for Designation (RFD), analyzing the product’s mechanism of action and synthesizing complex data for regulatory submission.
- Identified gaps in Pharmacokinetics (PK), Pharmacodynamics (PD), and toxicology testing; refined study plans with toxicology experts to strengthen safety assessments.
- Reviewed clinical data from similar products to shape early- and mid-phase clinical trial designs ensuring alignment with regulatory and clinical expectations.
- Delivered a comprehensive and strategic development roadmap guiding the Client through key drug development stages up to market approval.
- Strengthened the foundation for non-clinical and clinical development, supporting FDA readiness and clinical trial success.